低风险初产妇39周引产与期待治疗的比较:成本效果分析
引产减少剖宫产、妊娠期高血压疾病、死胎和新生儿死亡,但增加成本,增量成本效果比为每质量调整生命年87,691.91美元,结论为边际成本效果,是否常规开展取决于当地资源与患者意愿。
要点
- 39周引产较期待治疗减少剖宫产54,498例、妊娠期高血压疾病79,152例。
- 引产减少死胎795例、新生儿死亡11例,但增加臂丛神经损伤86例。
- 增量成本效果比为每质量调整生命年87,691.91美元,概率敏感性分析中仅65%概率具有成本效果。
核心结论
- 是否常规开展39周引产需取决于当地能力、医疗资源的审慎评估与分配以及患者意愿。
研究设计与样本
- 成本效果模型研究,使用TreeAge软件,比较39周引产与期待治疗。
- 模型输入来自文献,成本效果阈值设为每质量调整生命年100,000美元。
主要发现
- 引产组较期待治疗组减少剖宫产54,498例,减少妊娠期高血压疾病79,152例。
- 引产组较期待治疗组减少死胎795例、新生儿死亡11例,但增加臂丛神经损伤86例。
- 引产增加成本但增加质量调整生命年,增量成本效果比为每质量调整生命年87,691.91美元。
- 敏感性分析中,若引产成本增加180美元,则选择性引产不再具有成本效果。
- 若两种策略的剖宫产率相同,39周选择性引产不具有成本效果;蒙特卡洛模拟概率敏感性分析中引产仅65%的概率具有成本效果。
关键数值与推荐
- 成本效果阈值为每质量调整生命年100,000美元。
- 增量成本效果比为每质量调整生命年87,691.91美元。
- 引产成本增加180美元时,选择性引产不再具有成本效果。
临床怎么用
- 原文未据此给出常规开展39周引产的推荐,指出是否开展需取决于当地能力、医疗资源的审慎评估与分配以及患者意愿。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A large, recent multicenter trial found that induction of labor at 39 weeks for low-risk nulliparous women was not associated with an increased risk of cesarean delivery or adverse neonatal outcomes. OBJECTIVE: We sought to examine the cost-effectiveness and outcomes associated with induction of labor at 39 weeks vs expectant management for low-risk nulliparous women in the United States. STUDY DESIGN: A cost-effectiveness model using TreeAge software was designed to compare outcomes in women who were induced at 39 weeks vs expectantly managed. We used a theoretical cohort of 1.6 million women, the approximate number of nulliparous term births in the United States annually that are considered low risk. Outcomes included mode of delivery, hypertensive disorders of pregnancy, macrosomia, stillbirth, permanent brachial plexus injury, and neonatal death, in addition to cost and quality-adjusted life years for both the woman and neonate. Model inputs were derived from the literature, and a cost-effectiveness threshold was set at $100,000/quality-adjusted life years. RESULTS: In our theoretical cohort of 1.6 million women, induction of labor resulted in 54,498 fewer cesarean deliveries and 79,152 fewer cases of hypertensive disorders of pregnancy. We also found that induction of labor resulted in 795 fewer cases of stillbirth and 11 fewer neonatal deaths, despite 86 additional cases of brachial plexus injury. Induction of labor resulted in increased costs but increased quality-adjusted life years with an incremental cost-effectiveness ratio of $87,691.91 per quality-adjusted life year. In sensitivity analysis, if the cost of induction of labor was increased by $180, elective induction would no longer be cost effective. Similarly, we found that if the rate of cesarean delivery was the same in both strategies, elective induction of labor at 39 weeks would not be a cost-effective strategy. In probabilistic sensitivity analysis via Monte Carlo simulation, we found that induction of labor was cost effective only 65% of the time. CONCLUSION: In our theoretical cohort, induction of labor in nulliparous term women at 39 weeks of gestation resulted in improved outcomes but increased costs. The incremental cost-effectiveness ratio was marginally cost effective but would lead to an additional 2 billion dollars of healthcare costs. Whether individual clinicians and healthcare systems offer routine induction of labor at 39 weeks will need to depend on local capacity, careful evaluation and allocation of healthcare resources, and patient preferences. KEY WORDS: cesarean delivery, decision analysis, healthcare resources, induction of labor, low-risk nulliparous women, mode of delivery, obstetric outcomes.
引用
- Hersh AR, Skeith AE, Sargent JA, et al. Induction of labor at 39 weeks of gestation versus expectant management for low-risk nulliparous women: a cost-effectiveness analysis. Am J Obstet Gynecol. 2019. PMID: 30768934. doi:10.1016/j.ajog.2019.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。